Show simple item record

dc.contributor.authorQuer, Josep
dc.contributor.authorGregori, Josep
dc.contributor.authorRodríguez-Frias, Francisco
dc.contributor.authorButi, Maria
dc.contributor.authorMadejon, Antonio
dc.contributor.authorPerez-del-Pulgar, Sofia
dc.contributor.authorGarcia-Cehic, Damir
dc.contributor.authorCasillas, Rosario
dc.contributor.authorBlasi, Maria
dc.contributor.authorHoms, Maria
dc.contributor.authorTabernero, David
dc.contributor.authorAlvarez-Tejado, Miguel
dc.contributor.authorMuñoz, Jose Manuel
dc.contributor.authorCubero, Maria
dc.contributor.authorCaballero, Andrea
dc.contributor.authorCampo, Jose Antonio del
dc.contributor.authorDomingo, Esteban
dc.contributor.authorBelmonte, Irene
dc.contributor.authorNieto, Leonardo
dc.contributor.authorLens, Sabela
dc.contributor.authorMuñoz-de-Rueda, Paloma
dc.contributor.authorSanz-Cameno, Paloma
dc.contributor.authorSauleda, Silvia
dc.contributor.authorBes, Marta
dc.contributor.authorGomez, Jordi
dc.contributor.authorBriones, Carlos
dc.contributor.authorPerales, Celia
dc.contributor.authorSheldon, Julie
dc.contributor.authorCastells, Lluis
dc.contributor.authorViladomiu, Lluis
dc.contributor.authorSalmerón, Javier
dc.contributor.authorRuiz-Extremera, Angela
dc.contributor.authorQuiles-Pérez, Rosa
dc.contributor.authorMoreno-Otero, Ricardo
dc.contributor.authorLópez-Rodríguez, Rosario
dc.contributor.authorAllende, Helena
dc.contributor.authorRomero-Gómez, Manuel
dc.contributor.authorGuardia, Jaume
dc.contributor.authorEsteban, Rafael
dc.contributor.authorGarcia-Samaniego, Javier
dc.contributor.authorForns, Xavier
dc.contributor.authorEsteban, Juan Ignacio
dc.contributor.otherUAM. Departamento de Medicinaes_ES
dc.contributor.otherCentro de Biología Molecular Severo Ochoa (CBM)es_ES
dc.date.accessioned2016-07-20T14:46:07Z
dc.date.available2016-07-20T14:46:07Z
dc.date.issued2015-01-01
dc.identifier.citationJournal of Clinical Microbiology 53.1 (2015): 219-226es_ES
dc.identifier.issn0095-1137es_ES
dc.identifier.issn1098-660X (on line)es_ES
dc.identifier.urihttp://hdl.handle.net/10486/672182
dc.description.abstractHepatitisCvirus(HCV)is classified into seven major genotypesand67 subtypes. Recent studies haveshownthat inHCVgenotype 1-infected patients, response rates to regimens containingdirect-acting antivirals(DAAs)are subtype dependent. Currently available genotypingmethods have limited subtyping accuracy.Wehave evaluated theperformanceof adeep-sequencing-basedHCVsubtyping assay, developed for the 454/GS-Junior platform, in comparisonwith thoseof two commercial assays (VersantHCVgenotype 2.0andAbbott Real-timeHCVGenotype II)andusingdirectNS5Bsequencing as a gold standard (direct sequencing), in 114 clinical specimenspreviously tested by first-generation hybridization assay (82 genotype 1and32 with uninterpretable results). Phylogenetic analysis of deep-sequencing reads matched subtype 1 callingbypopulation Sanger sequencing(69%1b,31%1a) in 81 specimensandidentified amixed-subtype infection (1b/3a/1a) in one sample. Similarly,amongthe 32previously indeterminate specimens, identical genotypeandsubtype results were obtained by directanddeep sequencing in all but four samples with dual infection. In contrast, both VersantHCVGenotype 2.0andAbbott Real-timeHCVGenotype II failed subtype 1 calling in 13 (16%) samples eachandwere unable to identify theHCVgenotype and/or subtype inmore than half of the nongenotype 1 samples.Weconcluded that deep sequencing ismore efficient forHCVsubtyping than currently available methodsandallows qualitative identificationofmixed infectionsandmay bemorehelpfulwith respect to informing treatment strategies withnewDAA-containing regimens across allHCVsubtypesen_US
dc.description.sponsorshipThis study has been supported by CDTI (Centro para el Desarrollo Tecnológico Industrial), Spanish Ministry of Economics and Competitiveness (MINECO), IDI-20110115; MINECO projects SAF 2009-10403; and also by the Spanish Ministry of Health, Instituto de Salud Carlos III (FIS) projects PI10/01505, PI12/01893, and PI13/00456. CIBERehd is funded by the Instituto de Salud Carlos III, Madrid, Spain. Work at CBMSO was supported by grant MINECO-BFU2011-23604, FIPSE, and Fundación Ramón Areces. X. Forns received unrestricted grant support from Roche and has acted as advisor for MSD, Gilead, and Abbvie. M. Alvarez-Tejado, J. Gregori, and J. M. Muñoz work in Roche Diagnosticsen_US
dc.format.extent8 pag.es_ES
dc.format.mimetypeapplication/pdfen
dc.language.isoengen
dc.publisherAmerican Society for Microbiologyen_US
dc.relation.ispartofJournal of Clinical Microbiologyen_US
dc.rights© 2015, American Society for Microbiologyen_US
dc.subject.otherHepatitis Cen_US
dc.subject.otherAntiviralsen_US
dc.subject.otherHCVen_US
dc.titleHigh-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methodsen_US
dc.typearticleen
dc.subject.ecienciaMedicinaes_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1128/JCM.02093-14es_ES
dc.identifier.doi10.1128/JCM.02093-14es_ES
dc.identifier.publicationfirstpage219es_ES
dc.identifier.publicationissue1es_ES
dc.identifier.publicationlastpage226es_ES
dc.identifier.publicationvolume53es_ES
dc.relation.projectIDGobierno de España. IDI-20110115es_ES
dc.relation.projectIDGobierno de España. SAF 2009-10403es_ES
dc.relation.projectIDGobierno de España. BFU2011-23604,es_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionen_US
dc.rights.accessRightsopenAccessen
dc.facultadUAMFacultad de Medicina
dc.institutoUAMCentro de Biología Molecular Severo Ochoa (CBMSO)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record